Physician profile
Katrina Daae
NPI 1346661873
$972.95
in general payments reported to CMS, 2019-2025
20 companies · $883 in 2025
The $883 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $90.45 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.50 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $204.74 | 2024-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $158.71 | 2025 | |
| Lilly USA, LLC | $99.95 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $59.48 | 2025 | |
| Argenx US, INC. | $52.77 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Averitas Pharma INC. | $52.47 | 2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $39.45 | 2025 | Spravato |
| Pfizer INC. | $39.43 | 2025 | |
| Ucb, INC. | $38.84 | 2025 | Rystiggo |
| Lundbeck LLC | $36.29 | 2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $35.54 | 2025 | Ultomiris |
| Axsome Therapeutics, INC. | $20.45 | 2025 | Symbravo |
| Abiomed | $18.19 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2024 | Jardiance, Synjardy |
| Acadia Pharmaceuticals INC | $17.40 | 2025 | Nuplazid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.19 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2025 | |
| Sk Life Science, INC. | $16.43 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.90 | 2024 | Airsupra |
| Octapharma USA, INC. | $15.12 | 2024 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Daae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.